Investor Webinar
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that Nigel Theobald, Chief Executive Officer will be presenting at the ShareSoc Discovery Company Webinar on Tuesday, 25 February 2025 at 5.00 pm.
| N4 Pharma plc Nigel Theobald, Chief Executive Officer Luke Cairns, Executive Director | Via N4 Pharma Investor Hub Sign up at investors.n4pharma.com |
| Investor questions on this announcement We also invite investors to ask questions on this announcement via our investor hub | https://investors.n4pharma.com/link/0rJx8y |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0) 20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/James Pope | Tel: +44 (0) 20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0) 113 730 3896 |
About N4 Pharma
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn's disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.